Publication Name	World Journal of Gastroenterology
Manuscript ID	7216
Country	United States

Received	2013-11-09 10:29
Peer-Review Started	2013-11-09 21:08
To Make the First Decision	2013-12-04 09:11
Return for Revision	2013-12-16 10:45
Revised	2014-01-06 15:32
Second Decision	2014-03-19 13:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-03-19 15:21
Articles in Press	2014-05-23 09:56
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-07 13:15
Publish the Manuscript Online	2014-08-20 18:38

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Surgery
Manuscript Type	Topic Highlights
Article Title	Borderline resectable pancreatic cancer: Definitions and management
Manuscript Source	Invited Manuscript
All Author List	Nicole E Lopez, Cristina Prendergast and Andrew M Lowy
Funding Agency and Grant Number
Corresponding Author	Andrew M Lowy, MD, Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive #0987, La Jolla, CA 92093-0987, United States. alowy@ucsd.edu
Key Words	Pancreatic cancer; Borderline resectable pancreatic cancer; Neoadjuvant; Vascular resection; Pancreaticoduodenectomy; Whipple
Core Tip	Borderline resectable pancreatic cancer has become recognized as a clinical entity worthy of study based on a number of clinical observations that recognize a continuum between resectable and locally advanced unresectable disease. There are few prospective trials and therefore no data to support specific treatment regimens in borderline resectable pancreatic ductal adenocarcinoma (PDAC). Difficulties in achieving a consensus, objective definition, small numbers of patients and variability in therapeutic algorithms have delayed progress in establishing strong evidence-based practices for diagnosis and treatment. The Alliance trial represents a first step in establishing reproducible standards by which future trials in borderline resectable PDAC can abide.
Publish Date	2014-08-20 18:38
Citation	Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: Definitions and management. World J Gastroenterol 2014; 20(31): 10740-10751
URL	http://www.wjgnet.com/1007-9327/full/v20/i31/10740.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i31.10740

Full Article (PDF)	WJG-20-10740.pdf
Full Article (Word)	WJG-20-10740.doc
Manuscript File	7216-Review.docx
Answering Reviewers	7216-Answering reviewers.pdf
Copyright License Agreement	7216-Copyright assignment.pdf
Peer-review Report	7216-Peer reviewer(s).pdf
Scientific Editor Work List	7216-Scientific editor work list.doc